Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures

[1] Kanis JA(2021)SCOPE 2021: a new scorecard for osteoporosis in Europe Arch Osteoporos 16 82-46

[2] Norton N(2020)Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older Bone 134 1-1622

[3] Harvey NC(2020)American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update Endocr Pract 26 1595-714

[4] Soreskog E(2019)Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline J Clin Endocrinol Metab 104 695-26 e1

[5] Strom O(2022)Management of patients at very high risk of osteoporotic fractures through sequential treatments Aging Clin Exp Res 34 519-2957

[6] Spangeus A(2015)Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study Am J Med 128 2949-539

[7] Camacho PM(2018)ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis J Clin Endocrinol Metab 103 531-830

[8] Petak SM(2023)Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study Aging Clin Exp Res 35 819-658

[9] Binkley N(2023)Cost-effectiveness of sequential abaloparatide/alendronate in men at high risk of fractures in the United States Pharmacoeconomics 41 641-391

[10] Eastell R(2023)A systematic review of cost-effectiveness analyses of sequential treatment for osteoporosis Osteoporos Int 34 363-196

[1] Kanis JA(2021)SCOPE 2021: a new scorecard for osteoporosis in Europe Arch Osteoporos 16 82-46

[2] Norton N(2020)Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older Bone 134 1-1622

[3] Harvey NC(2020)American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update Endocr Pract 26 1595-714

[4] Soreskog E(2019)Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline J Clin Endocrinol Metab 104 695-26 e1

[5] Strom O(2022)Management of patients at very high risk of osteoporotic fractures through sequential treatments Aging Clin Exp Res 34 519-2957

[6] Spangeus A(2015)Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study Am J Med 128 2949-539

[7] Camacho PM(2018)ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis J Clin Endocrinol Metab 103 531-830

[8] Petak SM(2023)Sequential treatment of teriparatide and alendronate versus alendronate alone for elevation of bone mineral density and prevention of refracture after percutaneous vertebroplasty in osteoporosis: a prospective study Aging Clin Exp Res 35 819-658

[9] Binkley N(2023)Cost-effectiveness of sequential abaloparatide/alendronate in men at high risk of fractures in the United States Pharmacoeconomics 41 641-391

[10] Eastell R(2023)A systematic review of cost-effectiveness analyses of sequential treatment for osteoporosis Osteoporos Int 34 363-196